Peptides for Perimenopause Research – Complete Guide

Table of Contents

• Perimenopause Research Snapshot
• Perimenopause Research Landscape Overview
• How Peptides Are Being Studied for Perimenopause
• Major Perimenopause Peptides Under Investigation
• Current Perimenopause Research Landscape
• Perimenopause Clinical Pipeline and Trial Status
• Perimenopause Research Limitations and Evidence Gaps
• Regulatory and Research Classification
• Frequently Asked Questions About Perimenopause Peptide Research
• References

Perimenopause Research Snapshot

Peptides Under Investigation	More than 12 peptides and peptide-derived compounds appear in perimenopause research contexts, including kisspeptin, PT-141, CJC-1295, ipamorelin, tesamorelin, BPC-157, GHK-Cu, TB-500, and others
Research Maturity	Early-stage overall: kisspeptin has early human data; PT-141 has human trial data for low desire in women; GH secretagogues have human GH-response data; most others are preclinical or appear in wellness and clinical case contexts only
Most Studied Peptides	Kisspeptin (HPG axis research), PT-141 (sexual function), CJC-1295 and ipamorelin (GH secretion studies)
Primary Mechanisms Studied	HPG axis modulation via GnRH stimulation, melanocortin receptor activation for libido, growth hormone secretion to counter age-related GH decline, anti-inflammatory and tissue repair pathways
Clinical Trial Status	No completed Phase 1-3 clinical trials for any peptide specifically in perimenopause; PT-141 has human trials for hypoactive sexual desire disorder in women (not perimenopause-specific); no perimenopause-specific peptide trials identified on ClinicalTrials.gov from 2020-2025
Regulatory Classification	No peptides approved for perimenopause; BPC-157, CJC-1295, ipamorelin, TB-500 placed on FDA Category 2 restricted compounding list in 2023; approximately 14 expected to shift back to Category 1 compounding per February 2026 HHS announcement (not finalized as of March 2026)
WADA Status	Growth hormone secretagogues including CJC-1295 and ipamorelin are prohibited under WADA Class S2; PT-141, kisspeptin, BPC-157, GHK-Cu are not individually listed on the current prohibited list; athletes should verify against the current annual WADA list

Perimenopause Research Landscape Overview

Perimenopause is the biological transition that precedes menopause, typically beginning in a woman’s mid-to-late 40s and lasting anywhere from a few months to a decade. During this phase, the ovaries gradually reduce their output of estrogen and progesterone, producing wide hormonal fluctuations before levels ultimately settle at the lower postmenopausal baseline. These fluctuations drive a range of symptoms that can substantially affect quality of life, including hot flashes, night sweats, irregular menstrual cycles, disrupted sleep, mood changes, cognitive difficulties, reduced libido, and shifts in body composition toward increased abdominal fat and reduced muscle mass. The hypothalamic-pituitary-gonadal (HPG) axis, the hormonal control network connecting the brain to the ovaries, becomes dysregulated during this transition in ways that affect multiple physiological systems simultaneously. The established medical approach to managing perimenopause centers on menopausal hormone therapy (MHT), which directly replaces declining estrogen and progesterone. MHT has an extensive evidence base and is supported by large randomized controlled trials, though its risk-benefit profile varies with age, timing, and individual health factors. A 2023 systematic review and meta-analysis covering 34 randomized controlled trials and more than 27,000 participants found no overall cognitive benefit from MHT. A separate 2023 review of 51 studies reported increased dementia risk in postmenopausal women aged 65 and older on certain MHT formulations. MHT did improve sexual function in a 2023 analysis of 47 randomized controlled trials covering more than 15,000 participants. This nuanced picture is relevant context for understanding why researchers have begun exploring alternative and complementary approaches, including peptides. Peptide research for perimenopause is not a consolidated or well-developed field. No systematic reviews or meta-analyses specifically examining peptides for perimenopause exist as of 2025, which reflects the early state of the area rather than a settled negative finding. Interest comes from several converging directions: endocrinologists studying how neuropeptides like kisspeptin regulate the HPG axis during hormonal transitions, reproductive medicine researchers investigating the KNDy neuron system (a cluster of specialized hypothalamic neurons) as the source of hot flash physiology, and clinical practitioners exploring whether GH-stimulating peptides might offset the parallel decline in growth hormone that accompanies perimenopause. A growing wellness and clinical optimization community has also introduced a number of peptides into perimenopausal practice contexts, though this activity precedes and is not supported by clinical trial data. The Cenexa Labs Peptide Research Library covers the broader landscape of research across dozens of peptide categories, providing useful context for how perimenopause-relevant compounds are positioned relative to their evidence in other application areas.

How Peptides Are Being Studied for Perimenopause

HPG Axis and Neuroendocrine Regulation

The HPG axis is the hormonal chain of command that governs female reproductive function. The hypothalamus (a small brain region) releases a hormone called GnRH (gonadotropin-releasing hormone) in pulses. These pulses tell the pituitary gland to release LH and FSH, which in turn signal the ovaries to produce estrogen and progesterone. During perimenopause, this system becomes destabilized as declining ovarian hormone output disrupts the feedback signals that normally keep GnRH pulsing in a regular rhythm. Kisspeptin is a hypothalamic neuropeptide that functions as the primary upstream trigger for GnRH release. When kisspeptin binds to its receptor on GnRH-producing neurons, it initiates the cascade that ultimately drives LH and FSH secretion. Kisspeptin is therefore positioned at a critical regulatory node in the very system that goes awry during perimenopause. Researchers studying kisspeptin are not trying to replace estrogen directly. Instead, they are asking whether restoring or modulating kisspeptin signaling could help normalize the erratic GnRH pulsing patterns that underlie irregular cycles and hormonal fluctuations. Closely linked to kisspeptin is the KNDy neuron system. KNDy neurons in the arcuate nucleus of the hypothalamus co-express three signaling molecules: kisspeptin, neurokinin B (NKB), and dynorphin. Together, these three molecules form a self-regulating feedback loop that controls the pulse frequency of GnRH release. Estrogen normally keeps NKB neurons in check. When estrogen levels fall during perimenopause, this restraint is lifted and NKB neurons become hyperactive. This overactivation is now understood to be the direct neurological cause of hot flashes, not simply low estrogen itself. Understanding and potentially modulating the KNDy system is an active research direction with therapeutic implications that go beyond any single peptide compound.

Growth Hormone Axis Support

Growth hormone (GH) secretion declines progressively with age in both men and women, a process called somatopause. In women, this decline accelerates during and after the perimenopausal transition because estrogen normally promotes GH secretion. Falling estrogen therefore produces a compounded reduction in GH and its downstream mediator IGF-1 (insulin-like growth factor 1), which contributes to the changes in body composition, skin quality, energy levels, and recovery capacity that perimenopausal women commonly experience. GH-releasing peptides and growth hormone secretagogues work by stimulating the pituitary gland to release more of its own GH rather than introducing external GH directly. CJC-1295 is a modified GHRH (growth hormone-releasing hormone) analogue that binds GHRH receptors on pituitary cells. Ipamorelin is a ghrelin mimetic that activates the growth hormone secretagogue receptor (GHSR). Each works through a distinct receptor to trigger GH release, and they are frequently studied in combination because their mechanisms complement each other. Tesamorelin is another GHRH analogue with FDA approval for a specific fat redistribution condition in HIV patients and has been explored in clinical practice for age-related body composition changes. Research interest in these compounds for perimenopause centers on whether stimulating GH secretion could counteract somatopause-driven body composition shifts during the hormonal transition.

Melanocortin Receptor Activation for Sexual Function

Sexual desire and arousal involve brain-level signaling systems, not only peripheral hormones. The melanocortin system, a network of receptors throughout the central nervous system, plays a documented role in regulating sexual motivation. PT-141 (also known as bremelanotide) is a synthetic peptide that activates melanocortin receptors in the hypothalamus. This activation triggers the release of dopamine and other neurotransmitters associated with desire and arousal. Because PT-141 acts through a brain pathway rather than directly through estrogen or testosterone, it represents a mechanistically distinct approach to the libido decline that many perimenopausal women experience, one that does not depend on restoring hormone levels. PT-141 is the only peptide discussed in this article with completed human clinical trial data specifically for low sexual desire in women.

Tissue Repair, Anti-Inflammatory, and Dermatological Mechanisms

A separate cluster of research approaches examines peptides for the physical and structural changes that perimenopause accelerates, including joint discomfort, skin thinning and reduced collagen, and slower tissue recovery. BPC-157, a synthetic 15-amino acid peptide derived from a sequence found in human gastric juice, promotes angiogenesis (the growth of new blood vessels), modulates nitric oxide signaling, and has documented anti-inflammatory effects across multiple preclinical models. GHK-Cu is a copper-binding tripeptide naturally present in human plasma that stimulates collagen synthesis, activates wound healing pathways, and has been studied for effects on skin aging. TB-500 (Thymosin Beta-4) promotes tissue remodeling and reduces inflammation through actin-regulating mechanisms. None of these compounds have been studied in perimenopause-specific models, but the underlying biology connects to documented perimenopausal concerns about skin integrity, joint health, and recovery.

Major Perimenopause Peptides Under Investigation

This section covers nine peptides with published research relevant to perimenopause, ordered from those with the strongest or most direct human evidence to those at the earliest research stages. Given the general absence of perimenopause-specific trial data, “direct evidence” here means the compound has human trial data for a biologically related outcome, or robust preclinical evidence for a mechanism central to perimenopausal biology.

Kisspeptin

Kisspeptin is a 54-amino acid neuropeptide produced primarily in the hypothalamus, where it serves as the master regulator of reproductive hormone cascades. It belongs to the RF-amide peptide family and binds to a receptor called KISS1R (previously known as GPR54) on GnRH-secreting neurons. Kisspeptin is not simply a signaling molecule at the start of the reproductive hormone chain: it integrates information about nutritional status, stress, circadian rhythms, and estrogen levels to calibrate GnRH pulsatility. When estrogen falls during perimenopause, kisspeptin neurons in the arcuate nucleus become overactive in ways that correlate with irregular LH pulses and vasomotor symptoms. Published research in human volunteers has confirmed that intravenous kisspeptin administration stimulates LH and FSH release in both premenopausal and postmenopausal women, establishing proof of mechanism in humans. The pattern of LH response to kisspeptin differs between reproductive-age women and postmenopausal women, reflecting the changed hormonal environment and the altered sensitivity of the HPG axis. Studies in women with hypothalamic amenorrhea, a condition involving suppressed GnRH pulsatility, showed that kisspeptin infusion could restore pulsatile LH secretion, demonstrating that the GnRH neuron remains capable of responding when kisspeptin input is restored even in a suppressed state. For perimenopause specifically, the research interest is in whether kisspeptin modulation could help normalize the erratic hormonal fluctuations of the transition rather than simply replacing declining hormones. The current evidence comes from basic neuroendocrinology research rather than from perimenopause clinical trials. No perimenopause-specific kisspeptin trial has been registered or completed. Research on kisspeptin remains at the mechanistic and early human pharmacodynamics stage. Kisspeptin is available as a research peptide.

PT-141 (Bremelanotide)

PT-141 is a cyclic heptapeptide (seven amino acids in a ring structure) derived from **Melanotan I**I. Unlike melanotan II, which has broader melanocortin receptor activity, PT-141 was specifically developed to act through the central nervous system’s melanocortin pathway with a focus on sexual arousal signaling. It binds primarily to melanocortin receptor subtypes MC3R and MC4R in the hypothalamus and limbic system, triggering dopamine release and other neurotransmitter changes that increase sexual desire and motivation. PT-141 is the only peptide in this article with completed human clinical trials specifically for low sexual desire in women, though these trials enrolled women with hypoactive sexual desire disorder generally, not perimenopausal women as a defined population. The FDA approved bremelanotide as Vyleesi in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. This approval provides a unique reference point: PT-141 is the only peptide-derived compound with FDA approval for any female sexual function indication, though that approval does not extend to perimenopause specifically. The libido decline that perimenopausal women experience has both hormonal components (falling testosterone and estrogen) and central nervous system components, and PT-141’s mechanism targets the central component directly without influencing sex hormone levels. This makes it mechanistically distinct from hormone replacement approaches. Research availability is relevant here: PT-141 is available as a research compound, and its approved pharmaceutical form exists as Vyleesi for its indicated use. The PT-141 compound page at Cenexa covers the research in detail. Common side effects documented in clinical trials include nausea, flushing, and transient increases in blood pressure.

CJC-1295

CJC-1295 is a modified 29-amino acid analogue of growth hormone-releasing hormone (GHRH), engineered to resist enzymatic breakdown and bind to albumin in the bloodstream, which extends its active half-life substantially compared to native GHRH. Native GHRH has a half-life of only a few minutes because enzymes in the blood rapidly break it apart. CJC-1295 retains the GHRH receptor-binding capacity of the native hormone but persists long enough to produce sustained pituitary GH stimulation. A 2006 human pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism enrolled healthy adults and found that CJC-1295 produced a 2 to 10-fold increase in GH levels and a 1.5 to 3-fold increase in IGF-1 levels, with effects persisting for several days after a single dose, reflecting its extended half-life. This established human proof of mechanism for CJC-1295 as a GH secretagogue in adults, though the study did not focus on perimenopausal women or perimenopause-specific outcomes. Interest in CJC-1295 for perimenopause contexts stems from the documented somatopause that accompanies the perimenopausal transition. By stimulating the pituitary to release more GH, CJC-1295 may counteract the compounded GH decline driven by both aging and falling estrogen. Research on CJC-1295 for perimenopause-specific applications does not yet exist in peer-reviewed literature. CJC-1295 was placed on the FDA’s Category 2 restricted compounding list in 2023, though approximately 14 Category 2 peptides including CJC-1295 were expected to shift back to Category 1 compounding eligibility following a February 2026 HHS announcement, a change not fully finalized as of March 2026. CJC-1295 is classified as a growth hormone secretagogue and is prohibited under WADA Class S2. It is available as a research compound.

Ipamorelin

Ipamorelin is a synthetic pentapeptide (five amino acids) that acts as a selective growth hormone secretagogue receptor (GHSR) agonist. It mimics the action of ghrelin, the stomach-derived hormone that signals the pituitary to release GH, but does so with greater selectivity than earlier-generation GH secretagogues. The key differentiating feature of ipamorelin is that it stimulates GH release without meaningfully raising cortisol or ACTH (adrenocorticotropic hormone), the stress hormones that older ghrelin mimetics often elevated as an unwanted side effect. This selectivity profile makes ipamorelin particularly relevant to aging and perimenopausal research contexts, where elevated cortisol is already a documented concern and where avoiding stress hormone activation is a practical research priority. Preclinical studies have documented ipamorelin’s capacity to stimulate GH secretion in a pulsatile, physiologically consistent pattern rather than flooding the system with continuous GH elevation. In combination with CJC-1295, which prolongs GHRH receptor activation, ipamorelin produces complementary GH stimulation through the two receptor systems simultaneously. This combination is frequently referenced in clinical practice contexts for perimenopausal body composition support, though no peer-reviewed clinical trial data for this specific application exist. Ipamorelin was also placed on the FDA’s 2023 Category 2 restricted compounding list, with the same anticipated reclassification pathway as CJC-1295 following the 2026 HHS announcement. Like CJC-1295, it is prohibited under WADA Class S2 as a growth hormone secretagogue. Ipamorelin is available as a research compound.

Tesamorelin

Tesamorelin is a synthetic GHRH analogue with 44 amino acids, structurally similar to CJC-1295 but distinct in its development pathway. It is the only GH-stimulating peptide in this article with actual FDA approval, though that approval is limited to a specific and unrelated indication: HIV-associated lipodystrophy, a condition in which antiretroviral drug treatment causes abnormal fat accumulation in the abdomen. Tesamorelin’s approval in this context established that it can reduce visceral abdominal fat in adults through GH stimulation, a documented mechanism that has drawn clinical interest for its potential applicability to the abdominal fat redistribution that commonly occurs during perimenopause. Off-label exploration of tesamorelin for perimenopausal body composition changes appears in clinical practice case contexts rather than published clinical trials. One clinical case reference describes tesamorelin being used alongside GLP-1 receptor agonists and hormone therapy in a perimenopausal patient for abdominal fat reduction and muscle preservation. This represents clinical practice extrapolation from tesamorelin’s approved mechanism, not evidence from a perimenopause-specific trial. No peer-reviewed clinical trial of tesamorelin in perimenopausal women has been published. Tesamorelin is available through pharmaceutical research channels and requires appropriate prescribing authority for its approved indication.

BPC-157

BPC-157 is a synthetic pentadecapeptide of 15 amino acids derived from a protein sequence found in human gastric juice. It is one of the most extensively studied research peptides for tissue healing, anti-inflammatory, and angiogenic applications across preclinical models. The compound promotes angiogenesis (the growth of new blood vessels), upregulates growth hormone receptor expression, modulates nitric oxide production, and demonstrates consistent anti-inflammatory effects across multiple organ systems in rodent studies. A review published in the Journal of Physiology and Pharmacology noted no toxicity in animal models across a range of doses and administration routes. BPC-157 does not interact directly with estrogen or progesterone signaling and has no documented mechanism that would address the core hormonal fluctuations of perimenopause. Its relevance to perimenopausal research lies in the secondary and symptomatic dimension of the transition: joint discomfort, slower tissue recovery, sleep disruption, and the general increase in systemic inflammation that accompanies hormonal decline. These are areas where BPC-157’s documented preclinical mechanisms are biologically plausible contributors, even though no perimenopause-specific animal or human study has tested this connection directly. No human clinical trial data exist for BPC-157 in any indication. It was placed on the FDA’s 2023 Category 2 restricted compounding list. The anticipated 2026 reclassification discussed above is expected to restore compounding eligibility pending finalization. Research into BPC-157 and Organ Protection Research provides context for the breadth of systems this peptide has been studied in. BPC-157 is available as a research compound.

GHK-Cu

GHK-Cu is a copper-binding tripeptide (three amino acids: glycine, histidine, lysine) naturally present in human blood plasma, saliva, and urine. Plasma concentrations of GHK-Cu decline significantly with age, falling from approximately 200 nanograms per milliliter in young adults to roughly 80 nanograms per milliliter by age 60. This age-related decline, which coincides with the perimenopausal transition in women, has motivated research into whether supplementing GHK-Cu could counteract aging- and estrogen-withdrawal-related deterioration in skin, hair follicle health, and wound healing. GHK-Cu stimulates collagen synthesis in skin fibroblasts (the cells that produce the structural proteins holding skin together), promotes the formation of new blood vessels in wound-healing contexts, activates antioxidant enzymes, and regulates gene expression patterns associated with cellular repair. Topical formulations of GHK-Cu have been studied in cosmetic dermatology research and show effects on skin firmness, fine lines, and thickness consistent with its collagen-stimulating mechanism. Injectable forms of GHK-Cu have been explored in research contexts, though long-term human safety data for injectable GHK-Cu are absent from the published literature. The connection to perimenopausal skin concerns is mechanistically supported but not yet demonstrated in perimenopause-specific research. GHK-Cu is available as a research compound in both injectable and topical research formulations. Researchers interested in skin-related peptide compounds may also find the research on Snap-8 relevant to cosmetic peptide mechanisms.

TB-500 (Thymosin Beta-4 Fragment)

TB-500 refers to a synthetic fragment of thymosin beta-4, a naturally occurring 43-amino acid protein found in virtually every cell of the body. Thymosin beta-4 regulates the dynamics of actin, a structural protein that plays a central role in cell movement, wound repair, and inflammatory signaling. TB-500 specifically refers to the actin-binding region of thymosin beta-4, which researchers study for its effects on tissue regeneration, inflammation reduction, and recovery from injury. In preclinical models, TB-500 has demonstrated effects on wound closure, cardiac tissue repair after injury, and attenuation of inflammatory signaling. Reviews in Expert Opinion on Biological Therapy have documented its preclinical evidence base for tissue repair applications. Its perimenopause relevance lies in the joint discomfort, slower recovery from physical activity, and increased inflammatory tone that many women experience during the hormonal transition. Like BPC-157, TB-500 does not target the hormonal axis directly but may be relevant to the systemic physical consequences of declining estrogen. TB-500 lacks FDA approval for any indication and is prohibited under WADA Class S2 as a growth hormone secretagogue-related compound. It was among the peptides placed on the FDA’s 2023 Category 2 restricted compounding list. No human clinical trial data exist for TB-500 in perimenopause or any other indication. TB-500 is available as a research compound.

Hexapeptide-7

Hexapeptide-7 is a synthetic six-amino acid peptide that has been studied specifically in the context of menopausal and postmenopausal skin changes, making it the most directly perimenopause-relevant compound in terms of the research model used. Estrogen decline during and after perimenopause reduces skin thickness, elasticity, collagen content, and moisture retention. These changes reflect the direct role estrogen plays in maintaining dermal fibroblast activity and collagen production. A published study examining hexapeptide-7 in topical application found that it improved menopausal skin characteristics in models showing estrogen-related reductions in skin thickness and elasticity, countering the peri- and postmenopausal skin phenotype changes associated with hormonal decline. This represents one of the few instances where a peptide research study directly used a menopausal or perimenopausal skin model as its test system rather than general skin aging. The evidence base remains limited to this topical context. No injectable or systemic research on hexapeptide-7 has been identified, and no human clinical trial data beyond the topical model study exist. Hexapeptide-7 appears in cosmetic research formulations.

Current Perimenopause Research Landscape

The research ecosystem for peptides in perimenopause is best characterized as scattered and early-stage rather than as a coherent or rapidly advancing field. Unlike peptide research in neurodegenerative diseases or metabolic health, where defined research programs with organized funding streams have produced progressively deeper evidence bases, perimenopause peptide research lacks a unifying scientific program. Evidence comes from several distinct communities, none of which is primarily focused on perimenopause as a dedicated research area. Neuroendocrinology researchers studying HPG axis regulation have produced the most mechanistically rigorous work, particularly around kisspeptin and the KNDy neuron system. This work has clarified the neurological underpinnings of vasomotor symptoms at a level of detail not previously available, identifying NKB neuron hyperactivity as the proximate cause of hot flashes rather than low estrogen itself. This finding has therapeutic implications beyond peptides, driving development of NK3 receptor antagonists as non-hormonal hot flash treatments, but it also frames kisspeptin as a scientifically credible research target for HPG axis normalization during perimenopause. Clinical practitioners working in functional medicine, anti-aging medicine, and integrative gynecology have introduced a range of peptides into perimenopausal practice, primarily GH secretagogues (CJC-1295, ipamorelin, tesamorelin) and tissue-repair peptides (BPC-157, TB-500). This clinical activity precedes peer-reviewed trial data and operates on extrapolation from mechanistic evidence and clinical observation rather than controlled trial results. It creates a situation where use of these compounds in perimenopausal contexts exists in practice without the evidence base that would normally support it. Michigan State University received a $3.7 million research grant in 2025 to study perimenopause and psychosis, representing meaningful institutional investment in perimenopausal neuroscience. This work focuses on hormone-brain interactions rather than peptide interventions specifically, but it signals growing academic recognition of perimenopause as a distinct neurobiological transition worthy of dedicated research funding. This is relevant context for understanding where the field may develop over the next decade.

Perimenopause Clinical Pipeline and Trial Status

The perimenopause peptide clinical pipeline is, as of 2025, essentially empty. No peptide-specific clinical trials for perimenopause were identified in Phase 1, 2, or 3 status on ClinicalTrials.gov from 2020 through 2025. This is not a case of trials being conducted and producing negative results, which would itself be informative. It is a case of trials not having been initiated at all for this specific indication, reflecting the early stage of the field and the regulatory and funding realities facing research-use peptides. The absence of null results or failed perimenopause peptide trials does not indicate that compounds have performed well in trials that weren’t published. It indicates that the field has not advanced to the trial stage for this indication. For context, the active perimenopause clinical trial landscape is dominated by conventional hormone therapies and non-peptide pharmacologics. A trial of GLP2 (a GLP-1 and GIP receptor agonist, NCT07218445) for vasomotor symptoms is registered, representing the closest analog to a peptide-based approach in active trials, though GLP2 is not a traditional research peptide. Trials of fezolinetant, a neurokinin-3 receptor antagonist that works within the KNDy system biology described above, are ongoing for hot flash management. These non-peptide trials in the KNDy space are scientifically adjacent to kisspeptin and NKB research and may inform the design of future peptide trials targeting the same system. PT-141 is the one partial exception. While no PT-141 trial is specifically enrolled for perimenopause, bremelanotide completed trials in women with hypoactive sexual desire disorder resulting in FDA approval in 2019, and the perimenopausal libido decline that is the target of clinical interest in this population shares mechanistic features with the condition studied in those trials. The extension of that evidence to perimenopausal women specifically remains a research gap rather than a demonstrated finding. What the field needs to advance is straightforward in description if not in execution: dedicated Phase 2 trials with perimenopausal women as a defined population, standardized outcome measures that capture the multisymptom nature of perimenopause beyond any single domain, and long-term follow-up that can address the safety questions that current research cannot answer.

Perimenopause Research Limitations and Evidence Gaps

Human Data Constraints

The most fundamental limitation in perimenopause peptide research is the near-complete absence of human clinical trial data for this specific indication. No peptide discussed in this article has been tested in a randomized controlled trial using perimenopausal women as the defined study population. The human evidence that does exist comes from trials in adjacent but distinct populations: women with hypoactive sexual desire disorder (PT-141), healthy adults studied for GH pharmacokinetics (CJC-1295), HIV patients with fat redistribution (tesamorelin), and general reproductive endocrinology research subjects (kisspeptin). Each of these provides mechanistic or pharmacodynamic information relevant to perimenopause but cannot substitute for perimenopause-specific trial evidence. This situation contrasts sharply with the menopausal hormone therapy evidence base, which includes dozens of large randomized controlled trials enrolling tens of thousands of participants over decades of follow-up. The 2023 systematic review covering 34 MHT randomized controlled trials with more than 27,000 participants illustrates the scale of evidence that exists for conventional hormone therapy, making the peptide research gap particularly stark. For any researcher attempting to evaluate the evidence for perimenopause peptide research honestly, the conclusion is unavoidable: the field is operating almost entirely on mechanistic plausibility and clinical extrapolation. That is not a condemnation of the research questions, which are scientifically legitimate. It is a description of where the evidence currently sits.

Methodological Challenges

The preclinical models used for perimenopause research have specific limitations relevant to peptide testing. The two primary animal models, the ovariectomy model (surgical removal of the ovaries to mimic estrogen withdrawal) and the 4-vinylcyclohexene diepoxide (VCD) model (a chemical that gradually destroys ovarian follicles), each capture different aspects of the perimenopausal transition. Neither fully replicates the slow, variable, and fluctuating hormonal patterns of human perimenopause, which makes extrapolating animal findings to perimenopausal women particularly uncertain. A compound that shows benefit in an ovariectomy model is being tested in a system of complete and abrupt estrogen withdrawal, not the gradual transition that characterizes human perimenopause. No direct testing of the peptides discussed in this article in perimenopause-specific animal models has been published. BPC-157, TB-500, and GHK-Cu have been studied in various rodent models for their documented primary applications but not in ovariectomy or VCD models for perimenopause-relevant outcomes. This is a meaningful gap: even the preclinical evidence base specific to perimenopause is absent for most compounds. Standardization of protocols is also a challenge throughout the research-use peptide space. Variable compound quality, differing administration routes, inconsistent dosing schedules, and lack of consensus on which biomarkers should be tracked make it difficult to compare results across research groups or build a cumulative evidence base.

Knowledge Gaps

Several critical questions cannot be answered by available research. The long-term safety profiles of any discussed peptide in perimenopausal women are unknown. The theoretical cancer risk associated with tissue remodeling and GH-stimulating peptides, particularly for compounds like BPC-157, GHK-Cu, and the GH secretagogues, has not been confirmed or refuted by long-term human studies. Tumors associated with growth factor dysregulation may take decades to manifest, making short-term animal studies and brief human pharmacokinetic studies inadequate for safety assessment. The interaction effects between peptides and concurrent hormone therapy are completely unstudied. Many perimenopausal women who might be candidates for peptide research are also using MHT, and no data exist on how these approaches interact pharmacologically or whether they potentiate or antagonize each other’s effects. The optimal timing within the perimenopausal transition for any peptide intervention is unknown. The transition spans years, and the hormonal environment of early perimenopause differs substantially from that of late perimenopause, which likely affects both the mechanism of action and the appropriate targets for peptide intervention. None of the current research addresses this timing dimension. Head-to-head comparisons between different peptides targeting similar mechanisms, or between peptides and established hormone therapies, do not exist. Optimal delivery routes and dosing frequencies for perimenopausal applications are not established in peer-reviewed literature for any compound discussed here.

Regulatory and Research Classification

Current Status

FDA Classification: No peptide is FDA-approved for perimenopause or any perimenopausal symptom. FDA approval for MHT products including Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva applies only to those traditional hormone formulations. The FDA issued labeling updates for these products in 2025 and 2026, including initiating removal of black box warnings from certain MHT products, but these actions concern conventional hormone therapies exclusively and have no bearing on peptide classification. Among the peptides discussed in this article, tesamorelin holds FDA approval for HIV-associated lipodystrophy only. Bremelanotide (PT-141) holds FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women only. No other peptide discussed here holds FDA approval for any human indication. In 2023, the FDA placed BPC-157, CJC-1295, ipamorelin, TB-500, and approximately 15 other peptides on its Category 2 list, which restricts their use in compounded pharmaceutical preparations. On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 Category 2 peptides are expected to shift back to Category 1 status, which would restore their eligibility for prescription compounding. This reclassification had not been fully finalized as of March 2026. This regulatory change, if completed, would restore compounding access, not create a new therapeutic indication. These peptides would remain research-use compounds without approval for perimenopause. WADA Status: Growth hormone secretagogues including CJC-1295, ipamorelin, and TB-500 are prohibited under WADA Class S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times, both in- and out-of-competition. PT-141, kisspeptin, BPC-157, and GHK-Cu are not individually listed on the current WADA Prohibited List. Athletes should verify the status of any compound against the current annual WADA list, as the prohibited list is updated each year and individual compound status can change. Research Compliance: Researchers working with any of the compounds in this article require appropriate institutional oversight, including institutional review board approval for studies involving human participants or biological specimens. Peptide compounds acquired from research chemical suppliers for laboratory research should be obtained through suppliers with verified quality standards, including third-party testing. Researchers interested in sourcing quality peptides should consult resources on the Cenexa Pure Process for context on what manufacturing and purity standards to evaluate. For information about the current state of the research peptide supply landscape, the Peptide Sciences alternative page provides context on sourcing considerations following changes in the supplier landscape.

Research Context

The peptides discussed in this article are available for legitimate laboratory research purposes. They are not approved, validated, or recommended for human self-administration outside of properly supervised clinical research or pharmaceutical prescribing in the case of approved indications. Clinical practitioners exploring these compounds for perimenopausal applications should operate within appropriate regulatory frameworks, with biomarker monitoring, individualized assessment, and full disclosure of the investigational and non-approved nature of these uses. Foundational interventions including lifestyle optimization and, where appropriate, conventional hormone therapy represent the evidence-based foundation of perimenopausal care. Peptides are being studied as potential adjuncts, not replacements, for these established approaches.

Frequently Asked Questions About Perimenopause Peptide Research

Are there peptides that have been proven to help with perimenopause symptoms?

No peptides have been proven to help with perimenopause symptoms in clinical trials. PT-141 has FDA approval for a related condition (low sexual desire in premenopausal women) and has human trial data, but no trial has specifically studied perimenopausal women as a defined population for any peptide. The research field remains at the preclinical and early mechanistic stage for most compounds discussed in perimenopause contexts. Established hormone therapies have the strongest evidence base for managing perimenopausal symptoms.

What is kisspeptin and why are researchers interested in it for perimenopause?

Kisspeptin is a brain hormone that triggers the hormonal chain reaction leading to estrogen and FSH production. During perimenopause, the hormonal feedback system that regulates kisspeptin becomes dysregulated, contributing to irregular cycles and hot flashes. Researchers are interested in whether modulating kisspeptin signaling could help normalize erratic hormone fluctuations during the transition. Human studies have confirmed that kisspeptin administration stimulates LH and FSH release, establishing proof of mechanism, but perimenopause-specific trials have not yet been conducted.

Why are growth hormone peptides like CJC-1295 and ipamorelin discussed in perimenopause contexts?

Estrogen supports growth hormone secretion, so women experience an accelerated decline in GH during and after perimenopause on top of the normal age-related decrease. Lower GH contributes to increased abdominal fat, reduced muscle mass, declining skin quality, and reduced energy, symptoms that perimenopausal women commonly report. CJC-1295 and ipamorelin stimulate the pituitary gland to release more of its own GH, which is why clinicians exploring perimenopausal body composition have shown interest in them. However, no peer-reviewed clinical trial has tested either compound in perimenopausal women, and both are classified as prohibited substances under WADA regulations.

How does PT-141 differ from hormone therapy for addressing libido decline in perimenopause?

PT-141 (bremelanotide) works through a brain pathway called the melanocortin system, triggering dopamine release to increase sexual desire, rather than by replacing or supplementing sex hormones. Hormone therapy addresses libido partly through restoring estrogen and testosterone levels. These are mechanistically distinct approaches targeting different parts of the same symptom. PT-141 has human trial data and FDA approval for low sexual desire in premenopausal women, which gives it a stronger evidence foundation than most peptides discussed in perimenopause contexts, though perimenopause-specific trial data remain absent.

Are the peptides being studied for perimenopause safe to use?

Long-term safety data for any of the peptides discussed in perimenopause research contexts are absent from the published literature for perimenopausal women specifically. GH-stimulating peptides carry a theoretical cancer risk due to their tissue growth-promoting effects, which has not been confirmed or refuted by long-term human studies. Injectable forms of some compounds, including GHK-Cu, lack long-term human safety data. This does not mean these compounds are definitively unsafe, but it does mean that safety cannot be affirmatively confirmed from current evidence. Any research use of these compounds should involve appropriate clinical oversight and monitoring.

What is the difference between kisspeptin and the NKB system in perimenopause research?

These are related but distinct research targets within the same hormonal control system in the hypothalamus. Kisspeptin is a peptide that directly triggers GnRH release, the hormone that starts the chain of signals leading to estrogen production. Neurokinin B (NKB) is a co-signaling molecule expressed in the same neurons as kisspeptin. When estrogen falls during perimenopause, NKB neurons become overactive, and this overactivity is now understood to directly cause the neural signal that produces hot flashes. Kisspeptin is being studied as a potential therapy, while NKB is more prominently studied as a mechanism to explain hot flashes, with NKB receptor blockers (not peptides) being developed as therapeutic candidates targeting this pathway.

Will the 2026 FDA peptide reclassification make perimenopause peptide treatments available?

The anticipated reclassification of approximately 14 peptides from FDA Category 2 back to Category 1 status would restore eligibility for prescription compounding, not create new therapeutic approvals. Compounded peptides can be prescribed by physicians for specific patients, but their use would remain off-label since no perimenopause indication has been approved for any of these compounds. This regulatory change, if finalized, represents an access change for clinical practice rather than a change in the evidence base. These compounds would still lack clinical trial data supporting their use for perimenopause specifically.

References

1. Perimenopause and hormonal transition research context. PMC. PMC Article
2. Frontiers in Aging: metabolic and hormonal research in aging women. Frontiers in Aging. Full Article
3. Bonza Health physician blog: peptides in perimenopause, a cautiously curious perspective. Bonza Health. Article
4. VCD and ovariectomy animal models for perimenopause research: brain, behavior, and hormone studies. PMC. PMC Article
5. Perimenopause model research: hormonal and behavioral effects. PMC. PMC Article
6. Kisspeptin and HPG axis regulation: GnRH, LH, and FSH signaling. PMC. PMC Article
7. EMP-1 estrogen-mimetic peptide in vascular smooth muscle and high-glucose models. PubMed. PubMed
8. Systematic review: MHT and cognition, 34 RCTs. European Journal of Endocrinology. Article
9. Systematic review: MHT and sexual function. Climacteric (Taylor & Francis). Article
10. Complementary therapies for menopausal symptoms: 2025 review of 158 studies. Climacteric (Taylor & Francis). Article
11. PMC: MHT and neurological outcomes in perimenopause context. PMC. PMC Article
12. Michigan State University $3.7 million perimenopause and psychosis research grant, 2025. MSU Today. Article
13. FDA labeling changes for menopausal hormone therapy products. FDA. FDA Announcement
14. FDA: menopausal hormone therapies updated prescribing information. FDA. FDA Safety Page
15. HHS fact sheet: FDA initiates removal of black box warnings from menopausal hormone replacement therapy products. HHS. HHS Fact Sheet
16. FDA peptide reclassification 2026: Category 1 and Category 2 compounding changes. Meto. Article
17. Elite NP: FDA peptide reclassification 2026 implications for providers. Elite NP. Article
18. PMC: thymosin beta-4 and tissue repair research overview. PMC. PMC Article
19. PMC: perimenopause gut-brain axis and inflammatory cytokine research. PMC. PMC Article